glp-1 receptor agonists and cancer risk in adults with obesity GLP‐1 the for cancer: A meta‐analysis of randomized controlled trials - Silverii - 2025 - Diabetes, and Metabolism In a major new JAMA

The safety profile was consistent with GLP-1 class compounds

Research on obese mice suggests that unimolecular poly-pharmacology is an effective means to deal with various mechanisms leading to obesity and further indicates that GCGR activation is the distinguishing factor between single or double agonists and triple agonists of incretin receptors (127)

In clinical trials of Wegovy, participants lost an average of 15% of their body weight and more than half lost more

Furthermore, the dissociation rate with the receptor is slow, and the high affinity and slow dissociation with the receptor prolongs the time of pharmacological effect (58, 60)

We are running a global experiment at scale, with no long-term map